A Randomized, Double-Blind, Placebo-Controlled, Ascending, Single-Dose Study of the Safety, Tolerability and Bioeffect of Subcutaneous REGN 728 in Healthy Volunteers.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Ascending, Single-Dose Study of the Safety, Tolerability and Bioeffect of Subcutaneous REGN 728 in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Feb 2014

At a glance

  • Drugs REGN 728 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 01 Mar 2012 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Jan 2012 Trial status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
    • 07 Nov 2011 Company added as trial sponsor as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top